Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract A115: Alcohol use and molecularly defined colorectal cancer risks in a prospective study of older women
Razzak, Anthony, Tillmans, Lori S. , Wang, Alice H., Weisenberger, Daniel J. , Lynch, Charles F. , Anderson, Kristin E. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Oxentenko, Amy S. , Vierkant, Robert A. , Laird, Peter W. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Slager, Susan L. , Cerhan, James R. , Limburg, Paul J.

Mayo Clinic

Cancer Prevention Research | May 2, 2012 | Volume: 3 | Issue: 1_Supplement | Pages: A115-A115

10.1158/1940-6207.prev-09-a115 Get It

Abstract Background: Colorectal cancer (CRC) is the third most common incident cancer among women in the United States. Alcohol use has been proposed as a CRC risk factor, but existing observational data remain inconsistent. To date, relatively few studies have examined associations between alcohol use and CRC risk based on molecularly-defined subtypes. Aim: To evaluate associations between alcohol use and incident CRC overall, as well as by molecularly-defined subtypes including microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutation status in the prospective, population-based, Iowa Women's Health Study (IWHS). Methods: The IWHS recruited 41,836 randomly selected Iowa women, ages 55–69 years at enrollment, in 1986. Women with prevalent cancers or no follow-up were excluded, leaving 38,001 eligible for this study. Alcohol use was obtained from a self-administered food frequency questionnaire at study baseline. Incident CRCs were identified through annual linkage with the State Health Registry of Iowa. Archived, paraffin-embedded tissue specimens were recently requested for incident CRC cases diagnosed through December 31, 2002. In the present study, useable tissue specimens were obtained and molecularly characterized for 563/1,255 cases (45%), whose baseline age, body mass index, physical activity level, total energy intake and alcohol use were similar to non-retrieved cases (p > 0.05 for each comparison). Alcohol use was categorized as never (n=21,464), < 3.4 g/day (n=8,313) and > 3.4 g/day (n=8,224), based on the median split among users. Molecularly-defined CRC subtypes were categorized as MSI-high (MSIH; n=148), MSI-low or microsatellite stable (MSI-L/MSS; n=400); CIMP-positive (n=167) or CIMP-negative (n=368); and BRAF-mutation (n=154) or BRAF-wildtype (n=391). Relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated for alcohol use compared to never drinkers, using multivariable Cox regression models adjusted for body mass index, waist-to-hip ratio, smoking status, physical activity level, exogenous estrogen use, and daily intakes of total energy, total fat, red meat, sucrose, calcium, folate, methionine and vitamin E. Results: There was no statistically significant association between alcohol use and overall CRC risk (RR=1.00; 95% CI = 0.86–1.15 for < 3.4 g/day versus none; RR=1.06; 95% CI=0.91–1.24 for >3.4 g/day versus none). Further, there were no associations with alcohol use for specific, molecularly-defined CRC subtypes (RRs shown for > 3.4 g/day versus none): MSI-H (RR=1.07; 95% CI=0.70–1.64); MSI-L or MSS (RR=1.12; 95% CI=0.85–1.47); CIMP-positive (RR=0.97; 95% CI=0.64–1.47); CIMP-negative (RR=1.13; 95% CI=0.85–1.50); BRAF-mutation (RR=0.94; 95% CI=0.61–1.45); and BRAF-wildtype (RR=1.20; 95% CI=0.91–1.57). Conclusion: In this cohort of older women, alcohol use did not appear to be a risk factor for incident CRC, overall or by the defined molecular subtypes. Citation Information: Cancer Prev Res 2010;3(1 Suppl):A115.
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
Eisfeld, Ann‐Kathrin , Marcucci, Guido , Maharry, Kati , Schwind, Sebastian , Radmacher, Michael D., Becker, Heiko , Mrózek, Krzysztof , Whitman, Susan P., Metzeler, Klaus H. , Mendler, Jason H. , Wu, Yue-Zhong, Liyanarachchi, Sandya , Baer, Maria R. , Powell, Bayard L., Carter, Thomas H. , Moore, Joseph O. , Kolitz, Jonathan E. , Wetzler, Meir , Larson, Richard A. , Tanner, Stephan M., Chapelle, Albert de la , Bloomfield, Clara D. , Nicolet, Deedra , Patel, Ravi Kumar , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | April 24, 2012 | Volume: 120 | Issue: 2 | Pages: 249-258

10.1182/blood-2012-02-408492 | PMID 22529287 Get It

Abstract High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene-expression profiling and miRNA-expression profiling were performed using microarrays. High miR-3151 expression was associated with shorter disease-free and overall survival, whereas high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In gene-expression profiling, high miR-3151 expressers showed down-regulation of genes involved in transcriptional regulation, posttranslational modification, and cancer pathways. Two genes, FBXL20 and USP40, were validated as direct miR-3151 targets. The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC. The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications.
Counterbalanced Swivel Fork
Nelson, Susan E.

Mayo Clinic

American Journal of Occupational Therapy | April 16, 2012 | Volume: 37 | Issue: 7 | Pages: 489-490

10.5014/ajot.37.7.489 | PMID 6614130 Get It

Adaptations for Independent Use of Cassette Tape Recorder/Radio by High-Level Quadriplegic Patients
Kelly, Susan Nelson

Mayo Clinic

American Journal of Occupational Therapy | April 16, 2012 | Volume: 37 | Issue: 11 | Pages: 766-767

10.5014/ajot.37.11.766 | PMID 6650649 Get It

Predicting missing biomarker data in a longitudinal study of Alzheimer disease
Lo, Raymond Y. , Jagust, William J. , Aisen, Paul , Gamst, Anthony, Soares, Holly , Montine, Tom, Thomas, Ronald G. , Walter, Sarah , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Kornak, John , Buckholtz, Neil, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Marzloff, George, Toledo-Morrell, Leylade, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , Brand, Connie, Richard, Jennifer, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , MBBCH, Neill R Graff-Radford, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Benincasa, Amanda L., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy , Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Turner, Scott, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Sabbagh, Marwan N. , Connor, Donald J., Jacobson, Sandra A. , Jayam‐Trouth, Annapurni , Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Potkin, Steven, Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Marenberg, Marjorie E., Rovner, Barry W. , Anderson, Karen, Santulli, Robert B. , Englert, Jessica, Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Cohen, Ronald, Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Jack, Clifford R. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Chen, Kewei , Morris, John C. , Lee, Virginia M.‐Y. , Harvey, Danielle , Saykin, Andrew J. , Foroud, Tatiana , Potkin, Steven G. , Shen, Li , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Tang, Cheuk Ying , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , López, Oscar L. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , Martínez, Walter Fabián , Sperling, Reisa Anne , Rentz, Dorene M. , Killiany, Ronald , Norbash, Alexander , Nair, Anil K. , Obisesan, Thomas O. , Wang, Paul C. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Preda, Adrian , Hsiung, Gink-Yuek

Mayo Clinic

Neurology | April 5, 2012 | Volume: 78 | Issue: 18 | Pages: 1376-1382

10.1212/wnl.0b013e318253d5b3 | PMID 22491869 Get It

SSBP2 Variants Are Associated with Survival in Glioblastoma Patients
Xiao, Yuanyuan , Decker, Paul A. , Rice, Terri, McCoy, Lucie , Smirnov, Ivan, Patoka, Joseph S., Hansen, Helen M. , Wiemels, Joe, Tihan, Tarık , Prados, Michael D. , Chang, Susan M. , Kosel, Matthew , Buckner, Jan C. , Thompson, Reid C., Nabors, Burt , Brem, Steve, Madden, Melissa H., Browning, James E., Egan, Kathleen M. , Jenkins, Robert B. , Wrensch, Margaret , Decker, Paul A. , Berger, Mitchel S. , Fridley, Brooke L. , Lachance, Daniel Honore , O’Neill, Brian Patrick , Olson, Jeffrey J. , Wiencke, John K. , Nabors, Louis Burt

Mayo Clinic

Clinical Cancer Research | April 4, 2012 | Volume: 18 | Issue: 11 | Pages: 3154-3162

10.1158/1078-0432.ccr-11-2778 | PMID 22472174 Get It

Abstract Purpose: Glioblastoma is a devastating, incurable disease with few known prognostic factors. Here, we present the first genome-wide survival and validation study for glioblastoma. Experimental Design: Cox regressions for survival with 314,635 inherited autosomal single-nucleotide polymorphisms (SNP) among 315 San Francisco Adult Glioma Study patients for discovery and three independent validation data sets [87 Mayo Clinic, 232 glioma patients recruited from several medical centers in Southeastern United States (GliomaSE), and 115 The Cancer Genome Atlas patients] were used to identify SNPs associated with overall survival for Caucasian glioblastoma patients treated with the current standard of care, resection, radiation, and temozolomide (total n = 749). Tumor expression of the gene that contained the identified prognostic SNP was examined in three separate data sets (total n = 619). Genotype imputation was used to estimate hazard ratios (HR) for SNPs that had not been directly genotyped. Results: From the discovery and validation analyses, we identified a variant in single-stranded DNA-binding protein 2 (SSBP2) on 5q14.1 associated with overall survival in combined analyses (HR, 1.64; P = 1.3 × 10−6). Expression of SSBP2 in tumors from three independent data sets also was significantly related to patient survival (P = 5.3 × 10−4). Using genotype imputation, the SSBP2 SNP rs17296479 had the strongest statistically significant genome-wide association with poorer overall patient survival (HR, 1.79; 95% CI, 1.45-2.22; P = 1.0 × 10−7). Conclusion: The minor allele of SSBP2 SNP rs17296479 and the increased tumor expression of SSBP2 were statistically significantly associated with poorer overall survival among glioblastoma patients. With further confirmation, previously unrecognized inherited variations influencing survival may warrant inclusion in clinical trials to improve randomization. Unaccounted for genetic influence on survival could produce unwanted bias in such studies. Clin Cancer Res; 18(11); 3154–62. ©2012 AACR.
Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, Un Jung , Auinger, Peggy , Fahn, Stanley, Oakes, David , Shoulson, Ira , Kieburtz, Karl, Rudolph, Alice, Seibyl, John , Olanow, C. Warren , Tanner, Caroline M., Schifitto, Giovanni , Zhao, Hongwei , Reyes, Lydia, Shinaman, Aileen, Comella, Cynthia L., Blasucci, Lucia M., Samanta, Johan, Stacy, Mark, Williamson, Kelli, Harrigan, Mary, Greene, Paul, Ford, Blair, Moskowitz, Carol, Truong, Daniel , Pathak, Mayank , Jankovic, Joseph, Ondo, William G. , Atassi, Farah, Hunter, Christine , Jacques, Carol, Lannon, Margaret C., Russell, David , Jennings, Danna , Fussell, B., Schwarzschild, Michael A. , Growdon, John H., Tennis, Marsha, Gauthier, Serge , Panisset, Michel , Hall, Jean, Gancher, Stephen T., Hammerstad, John P., Stone, Claudia, Alexander-Brown, Barbara, Molho, Eric , Brown, Diane, Evans, Sharon, Manyam, Bala V., Simpson, Patricia , Wulbrecht, Brian, Whetteckey, Jacqueline, Roberts, Ted E, King, Pamela, Zesiewicz, Theresa A. , Gauger, Lisa, Trugman, Joel M. , Wooten, G. Frederick, Rost‐Ruffner, Elke, Suchowersky, Oksana , Ranawaya, Ranjit, Wood, Susan M. , Pantella, Carol , Kurlan, Roger, Richard, Irene Hegeman, Pearson, N. Shirlene, Caviness, John N., Adler, Charles, Lind, Marlene, Siderowf, Andrew , Colcher, Amy, Lloyd, Mary, Weiner, William J., Shulman, Lisa M. , Koller, William C., Lyons, Kelly , Feldman, Robert G., Ellias, Samuel A., Thomas, Cathi-Ann, Juncos, Jorge L., Watts, Ray L., Partlow, Anna, Tetrud, James W., Togasaki, Daniel M., Stewart, Tracy, Mark, Margery H., Sage, Jacob I., Caputo, Debbie, Gould, Harry J. , Rao, Jayaraman, McKendrick, A. D., Brin, Mitchell F. , Danisi, Fabio , Benabou, Reina, Hubble, Jean, Paulson, George W., Reider, Carson, Birnbaum, Alex, So, Julie , Dubinsky, Richard , Uitti, Ryan J. , Turk, Margaret F., Rottenberg, David A., Hansen, Joy, Ramos, Serrano, Waters, Cheryl , Lew, Mark, Welsh, Mickie, Kawai, Connie, OʼBrien, Christopher , Kumar, Rajeev , Seeberger, Lauren , Judd, Deborah, Mendis, Tilak, Grimes, David A. , Sutherland, Laura, Dawson, Ted M. , Reich, Stephen G. , Frey, Kirk A. , Wernette, K., Marek, Kenneth , Lang, Anthony E. , Goetz, Christopher G. , Jankovic, Joseph, Friedman, Joseph H. , Standaert, David G. , Factor, Stewart Alan , Clark, Jeffrey N. , Martin, W. R. Wayne , Hauser, Robert A. , Perlmutter, Joel S. , Racette, Brad A. , Simuni, Tanya , Saint‐Hilaire, Marie , Miyasaki, Janis M. , Johnston, Lisa , Pahwa, Rajesh , Wszołek, Zbigniew K. , Tuite, Paul , Barclay, Corlane , Dunlop, Rebecca A. , Albin, Roger L.

Mayo Clinic

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675 Get It

Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women
Limsui, David, Vierkant, Robert A. , Tillmans, Lori S. , Wang, Alice H., Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Cerhan, James R. , Limburg, Paul J. , Slager, Susan L. , Cerhan, James R , Vierkant, Robert A , Haile, Robert W , Potter, John D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 29, 2012 | Volume: 21 | Issue: 4 | Pages: 681-684

10.1158/1055-9965.epi-11-1168 | PMID 22337533 Get It

Abstract Background: Postmenopausal hormone (PMH) therapy represents a controversial colorectal cancer (CRC) preventive intervention. Because colorectal carcinogenesis is a heterogeneous process, we evaluated associations between PMH therapy and incident CRC in relation to KRAS mutation status in a population-based cohort of older women [Iowa Women's Health Study (IWHS)]. Methods: The IWHS enrolled 41,836 randomly selected women, ages 55 to 69 years, in 1986. PMH therapy and other exposure data were recorded at baseline. Tissue samples from prospectively identified CRC cases (n = 507) were analyzed for somatic KRAS mutations (exon 2, codons 12 and 13). Multivariable Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI). Results: PMH therapy (ever vs. never) was inversely associated with KRAS mutation–negative (RR = 0.83; 95% CI, 0.66–1.06; P = 0.14) and KRAS mutation–positive (RR = 0.82; 95% CI, 0.58–1.16; P = 0.27) tumors, although the observed risk estimates were not statistically significant. When anatomic subsite was additionally considered, the strongest association was found for KRAS mutation–negative, distal colorectal tumors (RR = 0.64; 95% CI, 0.43–0.96; P = 0.03). Conclusions: To our knowledge, we provide the first report of KRAS-defined CRC risks associated with PMH therapy. These data suggest that PMH therapy may reduce CRC risk through mechanisms beyond KRAS mutation status but might provide greater benefits for KRAS mutation–negative than mutation-positive tumors (at least in the distal colorectum). Impact: Findings from this prospective cohort study provide novel insights about the molecular biology of PMH therapy–related CRC risk reduction. Cancer Epidemiol Biomarkers Prev; 21(4); 681–4. ©2012 AACR.
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2
Gaudet, Mia M. , Antoniou, Antonis C. , Ramus, Susan J. , Kuchenbaecker, Karoline , Soucy, Penny, Chen, Xiaoqing, Kirchhoff, Tomas , McGuffog, Lesley, Barrowdale, Daniel , Healey, Sue, Sinilnikova, Olga M., Andrulis, Irene L. , Özçelik, Hilmi, Mulligan, Anna Marie , Thomassen, Mads , Gerdes, Anne‐Marie , Jensen, Uffe Birk , Skytte, Anne‐Bine , Kruse, Torben A., Caligo, Maria A. , Wachenfeldt, Anna von , Barbany, Gisela , Loman, Niklas, Soller, Maria , Ehrencrona, Hans , Karlsson, Per , Nathanson, Katherine L. , Rebbeck, Timothy R., Jakubowska, Anna , Lubiński, Jan , Jaworska, Katarzyna, Durda, Katarzyna, Złowocka, Elżbieta, Huzarski, Tomasz , Byrski, Tomasz , Cybulski, Cezary, Górski, Bohdan , Osório, Ana , Durán, M. , Tejada, María‐Isabel , Hamann, Ute, Hogervorst, Frans B.L., Os, Theo A. van, Leeuwen, Flora E. van , Meijers‐Heijboer, Hanne , Blok, Marinus J. , Kets, Marleen, Hooning, Maartje J. , Oldenburg, Rogier A., Ausems, Margreet G.E.M. , Peock, Susan, Frost, Debra, Ellis, Steve D., Platte, Radka, Fineberg, Elena, Evans, D. Gareth , Jacobs, Chris , Eeles, Rosalind A. , Adlard, Julian , Davidson, Rosemarie, Eccles, Diana M., Cole, Trevor, Paterson, Joan, Brewer, Carole, Douglas, Fiona, Hodgson, Shirley V. , Walker, Lisa, Porteous, Mary, Kennedy, M. John, Side, Lucy, Bove, Betsy, Fassy-Colcombet, Marion, Castéra, Laurent , Cornelis, François, Mazoyer, Sylvie , Léoné, Mélanie, Boutry‐Kryza, Nadia, Paillerets, Brigitte Bressac–de , Coupier, Isabelle, Delnatte, Capucine, Akloul, Linda, Lynch, Henry T., Snyder, Carrie, Daly, Mary B., Terry, Mary Beth , John, Esther M. , Miron, Alexander, Southey, Melissa C. , Goldgar, David E., Singer, Christian F., Rappaport, Christine , Tea, Muy‐Kheng M., Fink-Retter, Anneliese, Hansen, Thomas van Overeem , Nielsen, Finn C., Arason, Aðalgeir , Vijai, Joseph , Shah, Sohela, Sarrel, Kara , Piedmonte, Marion, Phillips, Kelly, Basil, Jack, Rubinstein, Wendy S. , Boggess, John F., Wakeley, Katie, Montagna, Marco , Imyanitov, Evgeny N., Janavičius, Ramūnas , Lázaro, Conxi , Blanco, Ignacio , Feliubadaló, Lídia , Brunet, Joan , Gayther, Simon A. , Odunsi, Kunle , Walsh, Christine , Oláh, Edith , Teo, Soo‐Hwang , Ganz, Patricia A. , Beattie, Mary, Rensburg, Elizabeth J. van , Dorfling, Cecelia M., Dı́ez, Orland , Kwong, Ava , Schmutzler, Rita K., Wappenschmidt, Barbara, Engel, Christoph , Meindl, Alfons , Ditsch, Nina , Arnold, Norbert , Heidemann, Simone , Niederacher, Dieter , Preisler‐Adams, Sabine, Gadzicki, Dorothea, Varon-Mateeva, Raymonda, Deißler, Helmut , Gehrig, Andrea, Sutter, Christian , Kast, Karin, Fiebig, Britta, Heinritz, Wolfram, Caldes, Trinidad, Hoya, Miguel de la , Muranen, Taru , Nevanlinna, Heli , Spurdle, Amanda B. , Ding, Yuan Chun , Lindor, Noralane M. , Fredericksen, Zachary, Pankratz, V. Shane , Peterlongo, Paolo , Manoukian, Siranoush , Peissel, Bernard , Zaffaroni, Daniela , Barile, Monica, Bernard, Loris, Viel, Alessandra , Giannini, Giuseppe , Varesco, Liliana , Radice, Paolo , Greene, Mark H. , Mai, Phuong L., Easton, Douglas F., Chenevix‐Trench, Georgia , Offit, Kenneth, Simard, Jacques , Durocher, Francine , Eccles, Diana , Thorne, Heather , Phillips, Kelly‐Anne , Couch, Fergus J. , Beesley, Jonathan , Chen, Xiaoqing, Wang, Xianshu , Lee, Andrew , Domchek, Susan M. , Gronwald, Jacek , Benı́tez, Javier , Wijnen, Juul , Eccles, Diana M., Cook, Jackie A , Morrison, Patrick J. , Kennedy, M. John, Godwin, Andrew K. , Stoppa‐Lyonnet, Dominique , Caron, Olivier , Pujol, Pascal , Buys, Saundra S. , Chung, Wendy K. , Hopper, John L. , Singer, Christian F. , Robson, Mark E. , Phillips, Kelly, Toland, Amanda Ewart , Agata, Simona , Isaacs, Claudine , Pharoah, Paul D.P. , Karlan, Beth Y. , Meindl, Alfons , Varon-Mateeva, Raymonda, Caldes, Trinidad, Tischkowitz, Marc D. , Neuhausen, Susan L. , Mai, Phuong L., Nevanlinna, H , Caligo, Maria A , Peterlongo, Paolo , Ramus, Susan J , Spurdle, Amanda B , Teo, Soo H , van Rensburg, Elizabeth J , Eccles, Diana , de la Hoya, Miguel , Diez, Orland , Radice, Paolo , Adlard, Julian , Arnold, Norbert , Brunet, Joan , Eeles, Rosalind A , Ehrencrona, Hans , Evans, D Gareth , John, Esther M , Joseph, Vijai , Southey, Melissa C , Jakubowska, Anna , Muranen, Taru A , Nathanson, Katherine L , Arason, Adalgeir , Barrowdale, Daniel , Engel, Christoph , Lazaro, Conxi , Montagna, Marco , Viel, Alessandra , Simard, Jacques , Chenevix-Trench, Georgia , Huzarski, Tomasz , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Lubinski, Jan , Phillips, Kelly-Anne , Terry, Mary Beth , Kwong, Ava

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 29, 2012 | Volume: 21 | Issue: 4 | Pages: 645-657

10.1158/1055-9965.epi-11-0888 | PMID 22351618 Get It

Abstract Background: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Methods: Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40 studies were combined. Results: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07–1.27; P = 7.42 × 10−4] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73–0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94–1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05–1.29; P = 3.8 × 10−4) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10–1.52; P = 1.8 × 10−3). Conclusions: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers. Impact: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21(4); 645–57. ©2012 AACR.
Validation of the MycAssay Pneumocystis Kit for Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Specimens by Comparison to a Laboratory Standard of Direct Immunofluorescence Microscopy, Real-Time PCR, or Conventional PCR
McTaggart, Lisa R. , Wengenack, Nancy L. , Richardson, Susan E.

Mayo Clinic

Journal of Clinical Microbiology | March 15, 2012 | Volume: 50 | Issue: 6 | Pages: 1856-1859

10.1128/jcm.05880-11 | PMID 22422855 Get It

ABSTRACT Pneumocystis jirovecii pneumonia is a significant cause of morbidity and mortality in AIDS patients as well as those with non-HIV immunosuppressive diseases. To aid diagnosis, the commercial MycAssay Pneumocystis real-time PCR assay (Myconostica, Ltd., Manchester, United Kingdom) targeting the mitochondrial ribosomal large subunit (mtLSU) has been developed to detect P. jirovecii in bronchoalveolar lavage (BAL) specimens. Here, we validated this assay against a laboratory standard of direct immunofluorescence microscopy, a cdc2 real-time PCR assay, or conventional PCR and sequencing of mtLSU. While more sensitive than any of these three assays analyzed individually, the MycAssay Pneumocystis assay demonstrated 100% sensitivity, 100% specificity, a 100% negative predictive value, and a 100% positive predictive value for detecting the presence of P. jirovecii in BAL specimens compared to the laboratory standard. Of note, two samples with positive cycle threshold ( C T ) values according to the MycAssay Pneumocystis assay lacked exponential amplification curves and thus were deemed negative. Also negative according to the laboratory standard, these samples highlight the importance of examining the amplification curves, in addition to noting the C T values, when interpreting positive results. Comparison of the MycAssay Pneumocystis assay to a laboratory standard establishes this assay to be a highly sensitive and specific method for the detection of P. jirovecii in bronchoalveolar lavage specimens. The approach may also be useful for the clinical laboratory validation of other sensitive real-time PCR assays.